Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children

Journal of Infectious Diseases

Volumn 195, Issue 6, 2007, Pages 799-808

  Moormann, Ann M ^a   Chelimo, Kiprotich ^d   Sumba, Peter O ^d   Tisch, Daniel J ^b   Rochford, Rosemary ^c   Kazura, James W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; MEROZOITE SURFACE PROTEIN 1; PHYTOHEMAGGLUTININ; TUBERCULIN;

ARTICLE; BURKITT LYMPHOMA; CHILD; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS LATENCY; VIRUS PATHOGENESIS;

ADOLESCENT; ANIMALS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; HERPESVIRUS 4, HUMAN; HUMANS; KENYA; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES;

EID: 33847658332     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/511984     Document Type: Article

References (44)

1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46:218-23.
2. Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000; 18:574-83.
3. Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer 2007; 120:121-7.
4. Dalldorf G. Lymphomas of African children with different forms or environmental influences. JAMA 1962; 181:1026-8.
5. Mwanda OW, Rochford R, Moormann AM, Macneil A, Whalen C, Wilson ML. Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004;(Suppl 8):S68-77.
6. de-The G. The Epstein-Barr virus (EBV): a Rosetta stone for understanding the role of viruses in immunopathological disorders and in human carcinogenesis. Biomed Pharmacother 1985; 39:49-51.
7. Fleming AF. The epidemiology of lymphomas and leukaemias in Africa-an overview. Leuk Res 1985; 9:735-40.
8. Biggar RJ, Henle G, Bocker J, Lennette ET, Fleisher G, Henle W. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int J Cancer 1978; 22:244-50.
9. Henle G, Henle W. Observations on childhood infections with the Epstein-Barr virus. J Infect Dis 1970; 121:303-10.
10. Henle W, Henle G. The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt's lymphoma and cancer of the post-nasal space. East Afr Med J 1969; 46:402-6.
11. Moormann AM, Chelimo K, Sumba OP, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005; 191:1233-8.
12. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci USA 2005; 102:18093-8.
13. Rochford R, Hobbs MV, Gamier JL, Cooper NR, Cannon MJ. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 1993; 90:352-6.
14. Crawford DH, Iliescu V, Edwards AJ, Beverley PC. Characterisation of Epstein-Barr virus-specific memory T cells from the peripheral blood of seropositive individuals. Br J Cancer 1983; 47:681-6.
15. Thorley-Lawson DA. EBV the prototypical human tumor virus-just how bad is it? J Allergy Clin Immunol 2005; 116:251-61, quiz 262.
16. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989; 43:67-71.
17. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000; 54:19-48.
18. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31.
19. + T-cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998; 91:3875-83.
20. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol 2005; 3:182-7.
21. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol 1987; 61:1310-7.
22. Gunapala DE, Facer CA, Davidson R, Weir WR. In vitro analysis of Epstein-Barr virus: host balance in patients with acute Plasmodium falciparum malaria. I. Defective T-cell control. Parasitol Res 1990; 76:531-5.
23. Moss DJ, Burrows SR, Castelino DJ, et al. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer 1983; 31:727-32.
24. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 1984; 312:449-50.
25. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1978; 22:662-8.
26. Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol 2005; 79:5477-88.
27. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC, Kazura JW. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004; 72:5135-42.
28. Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. Am J Trop Med Hyg 2006; 74:585-90.
29. Cao K, Moormann AM, Lyke KE, et al. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 2004; 63:293-325.
30. Parra M, Hui G, Johnson AH, et al. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1. Infect Immun 2000; 68:2685-91.
31. Udhayakumar V, Anyona D, Kariuki S, et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 1995; 154:6022-30.
32. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 1999; 60:641-8.
33. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997; 349:1650-4.
34. Mwanda OW. Burkitt's lymphoma: the initial defining characteristics. East Afr Med J 2004;(Suppl 8):S63-7.
35. Urban BC, Ferguson DJ, Pain A, et al. Plasmodium falciparum- infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400:73-7.
36. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003; 197:143-51.
37. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-8.
38. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7:165-72.
39. Piriou E, Jansen CA, Dort K, et al. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol 2005; 175:2010-7.
40. Bejarano MT, Masucci MG. Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 1998; 92:4256-62.
41. Hugosson E, Montgomery SM, Premji Z, Troye-Blomberg M, Bjorkman A. Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol 2004; 26:111-7.
42. Lee EA, Palmer DR, Flanagan KL, et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002; 70:1417-21.
43. Reece WH, Plebanski M, Akinwunmi P, et al. Naturally exposed populations differ in their Tl and T2 responses to the circumsporozoite protein of Plasmodium falciparum. Infect Immun 2002; 70:1468-74.
44. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990;248:1230-4.